Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 323

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 323
---
 cost of establishing sales, marketing and distribution capabilities
for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our
own.

Until we can generate sufficient revenue to finance our cash requirements,
which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings,
collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. This additional funding
may not be sufficient for us to fund any of our products through regulatory approval.

To the extent that we raise additional capital through the sale of
common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. In addition, any debt
financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such
as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs
or grant licenses on terms that may not be favorable to us. We also may be required to seek collaborators for any of our product candidates
at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise
would seek to develop or commercialize ourselves. Market volatility and unforeseen events, such as the COVID-19 pandemic and the
conflict between Russia and Ukraine or in the Middle East, could also adversely impact our ability to access capital as and when needed.
If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale
back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research
and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results
of operations and cause the price of our common stock to decline.

We may be unable to obtain additional financing to adequately
capitalize the Company following the Business Combination or to fund the operations and growth of OSR and its subsidiaries, which could
adversely affect the future prospects of the Company.

We do not expect to have substantial proceeds from the Company’s
IPO in which to provide capital to the Company and fund its growth following the Business